IV Ketamine + Neuroplasticity = Relief
Ketamine IV, IM, or IN for Depression: Which is Best? (Does It Matter?)
Time Magazine – New Hope for Depression 2017
FDA Data Support Ketamine as Depression Therapy 2017
The pros and cons of ketamine for obsessive compulsive disorder (OCD)
Ketamine Is Showing Early Success With Treating OCD
Benzodiazepines and Alcohol and their effect on ketamine treatments
THE CASE FOR KETAMINE: 2017 IN REVIEW
Party Drug Ketamine Closer to Treating Depression
Once-popular party drug now used for severe depression
Ketamine Relieves Depression By Restoring Brain Connections
Novel Drugs for Depression
‘The Biggest Breakthrough in Depression Research’ in 50 Years Is … Ketamine?
This Could Be Big: Intravenous Ketamine for Fibromyalgia
IV Ketamine Rapidly Effective in PTSD
Recent Study Shows Ketamine Reduces Symptoms of PTSD
Could Ketamine Be Used to Vaccinate for Depression or PTSD?
Ketamine Rapidly Reduces OCD Symptom
Ketamine’s Rapid Effects in Depression and OCD: Cause for Hope and Caution
Insomnia, Suicide and the Redemptive Power of Ketamine
Depression Treatments Inspired By Club Drug Move Ahead In Tests
Ketamine May Help Extinguish Fearful Memories
Yale: ‘Magic’ Antidepressant May Hold Promise For PTSD
Ketamine-Induced Optimism: New Hope for the Development of Rapid-Acting Antidepressants
Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
VA uses ketamine to treat PTSD effectively
Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder
Use of Ketamine in Acute Cases of Suicidality
The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis
Ketamine for Depression: A Q&A with Psychiatrist Alexander Papp, MD
Yale scientists explain how ketamine vanquishes depression within hours
Rodriguez, Carolyn I et al. “Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.” Neuropsychopharmacology 38.12 (2013): 2475-2483.
Feder, Adriana et al. “Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.” JAMA psychiatry 71.6 (2014): 681-688.
Henderson, Theodore A. “Practical application of the neuroregenerative properties of ketamine: real world treatment experience.” Neural Regeneration Research 11.2 (2016): 195.
Scheuing, Lisa et al. “Antidepressant mechanism of ketamine: perspective from preclinical studies.” Frontiers in neuroscience 9 (2015).
Neuropharmacology. 2012 Jan;62(1):63-77. doi: 10.1016/j.neuropharm.2011.07.036. Epub 2011 Aug 3. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Sanacora G1, Treccani G, Popoli M. PMCID: PMC3205453
Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856-864.
Kudoh A, Takahira Y, Katagai H, Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg. 2002;95: 114-118.
Petroff OA (December 2002). “GABA and glutamate in the human brain”. Neuroscientist. 8 (6): 562–573. doi:10.1177/1073858402238515. PMID12467378. Glutamate is the main excitatory and GABA the main inhibitory neurotransmitter in the mammalian cortex
“Glutamate Receptors – Structures and Functions”. Centre of Synaptic Plasticity. University of Bristol. 2007-01-04. Retrieved 2009-12-07.